This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Vigabatrin, a GABAergic antiepileptic drug, has been used successfully for the treatment of patients with partial epilepsy. Vigabatrin irreversibly inhibits γ-aminobutyric acid (GABA) transaminase with resultant increased concentrations of GABA in the brain and retina.1 Visual field concentric constriction secondary to vigabatrin is a frequent side effect and in most cases is irreversible.2 It has been speculated that the underlying mechanism is either a direct effect of vigabatrin on the ganglion cells of the retina or a cytotoxic effect of a possible increased GABA concentration on retina cells.3
There have been no reports of an association between the use of vigabatrin and sensorineural hearing loss. We report a patient who developed progressive hearing loss and visual field constriction after 4 years of therapy with vigabatrin for partial epilepsy.
Case report.
A 14-year-old boy with a 9-year history of partial epilepsy presented to the University Neurology outpatient clinic at the end of July 2002 with a moderate (50 to 55 dB HL) bilateral sensorineural hearing loss …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
